Nautilus Biotechnology and Weill Cornell Medicine-Qatar Team Up to Apply Single Molecule Proteomics Tech to Parkinson’s

Nautilus Biotechnology and Weill Cornell Medicine-Qatar (WCM-Q) have launched a $1.6M Michael J. Fox Foundation–funded collaboration to study alpha-synuclein’s role in Parkinson’s disease. Combining WCM-Q’s PTM expertise with Nautilus’ single-molecule proteomics platform, the team will develop high-resolution assays to map alpha-synuclein proteoforms and advance diagnostics and therapeutic insights.